TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
N4 Pharma ( (GB:N4P) ) has issued an update.
N4 Pharma announced its strategic focus on advancing the Nuvec® RNA delivery platform, which has shown promising pre-clinical data for next-generation RNA delivery systems. The company has launched an expanded work program to enhance the commercial data package around Nuvec®, aiming to secure licensing agreements and integrate Nuvec® into external RNA drug development pipelines. This program includes key data packages on oral delivery, endosomal release, dual loading, manufacturing, targeting, toxicity, and pharmacokinetics, which are expected to add significant shareholder value and position Nuvec® as a preferred delivery platform in the market.
More about N4 Pharma
N4 Pharma is a UK-based biotechnology company focused on developing Nuvec®, a proprietary gene delivery system aimed at advancing therapies for cancer and other diseases. The company is positioned in the rapidly expanding field of RNA therapeutics, which is of significant interest to major pharmaceutical companies and biotech innovators.
Average Trading Volume: 1,691,883
Technical Sentiment Signal: Sell
Current Market Cap: £5.71M
For an in-depth examination of N4P stock, go to TipRanks’ Overview page.